Erdanat 5 — Erdafitinib 5 mg Tablets, 28 Tablets

Erdanat-5 (Erdanat 5) is supplied as round, film-coated oral tablets that provide structural protection and ensure uniform release of the active component in the gastrointestinal tract. Each tablet contains 5 mg of pure active ingredient Erdafitinib. The tablet core and film coating also incorporate a carefully formulated blend of excipients (including mannitol, microcrystalline cellulose, magnesium stearate, croscarmellose sodium, and hypromellose) that ensure physical stability, correct dissolution profile, and extended shelf life.

The drug is packaged in original white high-density polyethylene (HDPE) bottles containing 28 tablets per bottle. The bottle neck is equipped with a sealed tamper-evident membrane and a child-resistant closure system. Inside each bottle, a desiccant canister or sachet (silica gel) is placed to protect the tablets from atmospheric moisture and hydrolysis. Each bottle, along with an official comprehensive package insert, is packed into a branded outer cardboard box featuring security holograms and unique factory serial numbers.

Pharmacodynamics: Erdafitinib is a potent, small-molecule selective inhibitor of the enzymatic tyrosine kinase activity of FGFRs (fibroblast growth factor receptor types 1, 2, 3, and 4). In normal cells, FGFR receptors regulate cell growth, differentiation, survival, and angiogenesis. However, in urothelial carcinoma, somatic genetic alterations—mutations or genomic fusions in FGFR3 or FGFR2 genes—frequently occur, causing constitutive, ligand-independent receptor activation. Erdanat-5 (Erdanat 5) binds with high affinity to the ATP-binding domain of FGFR receptors, blocking autophosphorylation and completely interrupting downstream intracellular signaling cascades (including RAS/RAF/MEK/ERK and PI3K/AKT). This results in G1/S phase cell cycle arrest, profound inhibition of malignant cell proliferation, and induction of apoptosis.

Pharmacokinetics: Following oral administration, erdafitinib is rapidly and virtually completely absorbed into systemic circulation, reaching peak plasma concentration (Cmax) within 2 to 6 hours (median approximately 4 hours). Food intake does not exert a clinically meaningful effect on total bioavailability, permitting administration with or without food. Erdafitinib is extensively bound to human plasma proteins (predominantly alpha-1-acid glycoprotein and albumin) with a binding degree exceeding 99.7%. Metabolism occurs primarily in the liver via cytochrome P450 CYP2C9 and CYP3A4 isoenzymes. Excretion is mainly fecal (approx. 69% as metabolites and unchanged drug) and renal (approx. 19%). The mean elimination half-life (T1/2) ranges from 50 to 60 hours, maintaining stable therapeutic plasma levels with once-daily dosing.

Erdanat-5 (Erdanat 5) is indicated as monotherapy for the treatment of adult patients (aged 18 years and older) with the following clinical diagnoses:

• • Locally advanced or metastatic unresectable urothelial carcinoma (cancer of the bladder, ureters, renal pelvis, or urethra);
• • Documented presence of specific susceptible genetic alterations in FGFR3 or FGFR2 genes confirmed by a validated PCR or NGS assay (including FGFR3 mutations R248C, S249C, G370C, Y373C or FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BICC1, FGFR2-CASP7 fusions);
• • Disease progression during or following at least one line of prior systemic platinum-based chemotherapy (cisplatin, carboplatin), including disease recurrence within 12 months of neoadjuvant or adjuvant treatment.

Therapy with Erdanat-5 (Erdanat 5) must be initiated and managed exclusively under the supervision of a physician experienced in targeted antineoplastic therapy.

• Method of Administration: Tablets are swallowed whole with a sufficient volume of water (at least 100–150 mL) once daily at approximately the same time each day. Tablets must not be chewed, crushed, split, or dissolved prior to ingestion. May be taken with or without food.
• Starting Dosage: The recommended initial dose of erdafitinib is 8 mg once daily. To achieve this starting dose, the physician combines appropriate strengths (e.g., one 5 mg tablet + one 3 mg tablet).
• Dose Titration Protocol: Mandatory serum phosphate (inorganic phosphorus) assessment is performed 14 to 21 days after treatment initiation. If serum phosphate is < 5.5 mg/dL (1.78 mmol/L) and no severe drug-related toxicities are present, the dose is up-titrated to the maximum of 9 mg once daily.
• Dose Modifications & Special Precautions: In cases of severe hyperphosphatemia, significant ocular toxicity, or grade 3–4 dermatological adverse events, treatment should be temporarily withheld until symptom resolution, then resumed at a reduced dosage level (e.g., 6 mg or 5 mg daily). Hyperphosphatemia is managed with dietary restrictions (600–800 mg/day) and phosphate binders (sevelamer). Mandatory ophthalmologic monitoring (OCT and fundoscopy) is required baseline, at 1 and 2 months, then every 3 months thereafter.

The administration of Erdanat-5 (Erdanat 5) is strictly contraindicated in patients presenting with the following conditions:

• • Known hypersensitivity or severe allergic reactions to erdafitinib or any of the inactive ingredients contained within the tablet;
• • Severe hepatic impairment (Child-Pugh Class C);
• • Severe renal impairment (creatinine clearance < 30 mL/min by Cockcroft-Gault) or end-stage renal disease requiring hemodialysis;
• • Children and adolescents under 18 years of age (safety and efficacy have not been established in pediatric populations);
• • Pregnancy and lactation period (breastfeeding);
• • Concomitant use of strong CYP2C9 or CYP3A4 inhibitors/inducers where alternative agents cannot be substituted.

• CYP2C9 and CYP3A4 Inhibitors: Co-administration with strong inhibitors of these enzymes (e.g., ketoconazole, itraconazole, clarithromycin) significantly increases erdafitinib AUC and Cmax, elevating the risk of severe toxicities. Concomitant use should be avoided.
• CYP2C9 and CYP3A4 Inducers: Strong inducers (rifampin, carbamazepine, phenytoin, St. John's wort) substantially decrease plasma erdafitinib exposure, rendering therapy clinically ineffective.
• Phosphate-Altering Medications: Concomitant use with drugs that elevate serum phosphate levels should be avoided until steady-state phosphate levels are established.
• P-glycoprotein (P-gp) Substrates: Erdafitinib may alter systemic exposure to P-gp substrates with narrow therapeutic indices (e.g., digoxin), requiring careful monitoring.

The use of Erdanat-5 (Erdanat 5) during pregnancy is contraindicated. Based on its mechanism of action and findings from animal reproduction studies, erdafitinib can cause fetal harm, malformations, and embryo-fetal lethality when administered to a pregnant woman. A pregnancy test must be performed and confirmed negative prior to initiating treatment in females of reproductive potential.

Females of reproductive potential must use effective contraception during treatment with Erdanat-5 (Erdanat 5) and for at least 1 month after the final dose. Male patients with female partners of reproductive potential must use effective barrier contraception during treatment and for 1 month following the last dose. There are no data on the presence of erdafitinib or its metabolites in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment and for 1 month after the last dose.

Therapy with Erdanat-5 (Erdanat 5) is associated with a distinct adverse reaction profile directly related to systemic FGFR inhibition:

• • Laboratory and Metabolic Disorders: Hyperphosphatemia (occurs in over 76% of patients as a direct pharmacodynamic effect), hyponatremia, hypocalcemia, increased plasma ALT, AST, and alkaline phosphatase.
• • Dermatological Reactions: Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), severe skin dryness (xerosis), alopecia, onycholysis (detachment of the nail plate from the nail bed), nail dystrophy, paronychia.
• • Gastrointestinal Tract: Stomatitis and oral mucosal ulceration, dry mouth (xerostomia), diarrhea, nausea, vomiting, dysgeusia (taste distortion), decreased appetite, constipation.
• • Ophthalmological Disorders: Dry eye syndrome, blurred vision, central serous retinopathy, and retinal pigment epithelium detachment (requires routine ophthalmologic monitoring).
• • General Disorders: Fatigue, severe asthenia, dry mucous membranes, arthralgia, myalgia, and musculoskeletal pain.

Data regarding acute overdose with Erdanat-5 (Erdanat 5) in clinical practice remain limited. Ingestion of doses exceeding recommended levels results in severe exacerbation of reported adverse effects, particularly critical hyperphosphatemia, severe ulcerative stomatitis, cutaneous and nail toxicity, and ocular disturbances.

There is no known specific antidote for erdafitinib overdose. In the event of an accidental or intentional overdose, immediately discontinue the drug, perform gastric lavage or administer activated charcoal (if recent), and hospitalize the patient for supportive symptomatic care. Frequent biochemical monitoring of serum electrolytes and phosphorus is mandatory.

Erdanat-5 (Erdanat 5) should be stored in its original, tightly closed manufacturer bottle in a dry place protected from direct sunlight and atmospheric moisture at a temperature not exceeding 30 °C. Do not freeze. Keep out of reach of children and pets. Transportation must strictly adhere to regulations governing pharmaceutical transport to preserve packaging integrity and temperature control. Shelf life is 24 months (2 years) from the date of manufacture. Do not use after expiration date. Prescription status: Prescription only (Rx-only).

To protect patients from counterfeit products, Natco Pharma Ltd. implements a comprehensive multi-tier authenticity verification system for Erdanat-5 (Erdanat 5):

• ✅ Two-Layer QR Code Sticker: The top of the outer cardboard box features a proprietary two-layer (peel-off) security sticker. Peel back the top layer to reveal a unique digital QR code and hidden verification code. Scan the QR code using a smartphone camera to access the official Natco verification portal.
• ✅ Security Hologram & Embossing: The box incorporates an anti-counterfeiting hologram with dynamic optical effects and tactile embossed logos/lettering that can be distinctly felt by touch.
• ✅ Tamper-Evident Seals: Cardboard packaging is secured with factory seals, and the HDPE bottle neck features a child-resistant "push-and-turn" cap along with an intact hermetic foil seal membrane underneath.
• ✅ Batch & Expiry Consistency: Laser-engraved Batch Number, Manufacturing Date, and Expiration Date on the outer carton must precisely match the corresponding markings on the bottle label.